Latest News and Press Releases

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching ‘The Other TD’ campaignTD is a chronic movement disorder impacting one in four people who take certain...

Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR® (deutetrabenazine) extended-release tabletsPatients reported...

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-'749) and its long-term systemic...

More than 92% of schizophrenia patients taking TEV-'749 in the SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication1New data from UZEDY®...

REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines...

Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitisThe FDA previously approved...

The expansion of the strategic partnership reinforces the solid foundation of the collaborative efforts that commenced in April 2024The collaboration supports Teva's Pivot to Growth strategy and adds...

NurExone Welcomes Biopharma Executive Dr. Ram Petter to Drive Strategic Collaborations

More than $350,000 of Convertible Debt Eliminated BOCA RATON, FL, April 13, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group (OTC PINK: CTYX) has filed all required annual reports...

PHILADELPHIA, June 24, 2019 (GLOBE NEWSWIRE) -- A lawsuit was filed on June 20, 2019 in Montgomery County, Pennsylvania against Teva Pharmaceuticals USA, Inc. and Teva Branded Pharmaceuticals...